Open Access Open Access  Restricted Access Subscription Access

A Review of Therapeutic Potential of Psychedelic Compounds in Psychiatry

Sneha s Rajan, Aanina Basheer

Abstract


The Substance Act of 1970 classified psychedelic drugs under Schedule I, hindering psychiatric research progress. However, recent years have seen a resurgence in psychedelic therapy interest, showing promise in treating various mental health conditions. Psychedelics like psilocybin and MDMA have demonstrated efficacy in conditions such as depression, PTSD, and substance use disorders. Safety and regulatory challenges persist, emphasizing the need for careful supervision to ensure their therapeutic use.


Full Text:

PDF

References


https://www.tandfonline.com/doi/full/10.31887/DCNS.2019.21.2/dnutt

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4813425/

https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762%2823%2900146-1/fulltext

https://www.nature.com/articles/s41386-023-01656-7

https://www.theguardian.com/science/neurophilosophy/2014/sep/02/psychedelic-psychiatry


Refbacks

  • There are currently no refbacks.